Entrada Therapeutics, Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Entrada is a preclinical-stage biotechnology company developing intracellular medicines using its Endosomal Escape Vehicle (EEV) platform. It had not initiated clinical trials and had generated no revenue.
Financial results and liquidity
| Metric | Q2 2022 | First half 2022 | Comparable 2021 |
|---|---|---|---|
| Revenue | None | None | None |
| Research and development expense | $16.2 million | $32.0 million | $6.8 million Q2; $13.1 million first half |
| General and administrative expense | $7.3 million | $13.8 million | $3.1 million Q2; $5.3 million first half |
| Total operating expenses | $23.6 million | $45.7 million | $9.9 million Q2; $18.3 million first half |
| Net loss | $23.2 million | $44.9 million | $9.9 million Q2; $18.3 million first half |
| Operating cash flow | Not separately provided | $(39.0) million | $(16.2) million first half |
At June 30, cash and cash equivalents were $90.9 million and marketable securities were $153.4 million, totaling $244.3 million; restricted cash of $4.0 million was additional. Total assets were $295.9 million, total liabilities $39.9 million, and stockholders’ equity $256.0 million. The filing reports no borrowings; lease obligations were $29.9 million. No profit margin is meaningful given the absence of revenue and continuing losses.
First-half investing cash outflow was $157.3 million, primarily reflecting $182.7 million of marketable-security purchases, partly offset by $26.7 million of maturities, plus property and equipment purchases. Financing cash flow was $0.1 million, mainly option exercises. Cash, cash equivalents and restricted cash declined by $196.2 million during the period.
Changes versus prior period
- First-half net loss increased to $44.9 million from $18.3 million; operating expenses rose by $27.4 million. R&D expense increased by $18.9 million and G&A by $8.5 million.
- Management attributed higher R&D primarily to external research and preclinical work and increased headcount; higher G&A primarily reflected personnel, professional services and public-company insurance costs.
- Cash and cash equivalents fell from $291.1 million at year-end 2021, while the company invested in marketable securities. The company had no marketable securities at December 31, 2021.
- Basic and diluted loss per share was $0.74 for Q2 and $1.43 for the first half, compared with $7.56 and $14.16, respectively, in 2021. The share-count and IPO-related capital structure changed substantially, so per-share comparisons are not directly indicative of changes in underlying performance.
Outlook, risks and notable items
- Management expects existing cash, cash equivalents and marketable securities to fund operating expenses and capital needs into the second half of 2024. The liquidity note separately states the resources are expected to cover at least the next 12 months from issuance of the financial statements. Both estimates depend on assumptions, and additional financing will be needed to support longer-term plans.
- Entrada expected to file its first DMD-related IND for ENTR-601-44 in Q4 2022 and an IND for the DM1 candidate ENTR-701 in 2023. These are forward-looking targets, not completed milestones. It expected R&D and G&A spending to increase.
- Key risks include the unproven EEV approach, preclinical and regulatory uncertainty, reliance on third-party manufacturers and research organizations, manufacturing scale-up and supply risks, competition, intellectual-property protection, and the need to raise additional capital. The company cautioned that preclinical results may not predict clinical outcomes.
- Operating cash use and net losses are expected to continue; the company may never generate product revenue or achieve profitability. No material litigation was reported as probable to have a material adverse effect.
- Adoption of lease accounting standards in 2022 resulted in recognition of operating right-of-use assets and lease liabilities. A new 81,442-square-foot Boston lease had not commenced by June 30 and was therefore excluded from reported lease liabilities; it carries an approximately 10-year term and landlord tenant-improvement allowance of up to $19.5 million.
- Available-for-sale securities had $2.3 million of unrealized losses, attributed primarily to interest-rate changes; none had been in a continuous loss position for over 12 months, and no impairment was recorded. Management expected full recovery at maturity.
- Management expected 2022 tax rules requiring capitalization and amortization of research and development costs to reduce tax losses, but not to create an actual 2022 tax liability. Disclosure controls were assessed as effective at a reasonable-assurance level.
Important facts for investors to verify
- Whether ENTR-601-44 and ENTR-701 meet the stated IND timelines, and what preclinical or regulatory developments support those targets.
- Whether the $244.3 million of cash, cash equivalents and marketable securities remains sufficient through the projected second half of 2024, given spending growth and the new facility commitment.
- The timing, commencement conditions and expected cash impact of the new Boston lease and tenant improvements.
- Progress in manufacturing scale-up, supply reliability and third-party research arrangements for planned development programs.
- Potential dilution or changes to development plans if additional financing is required before product revenue is available.